Background: Despite the well-documented efficacy of Hymenoptera specific immunotherapy (SIT), there is no safe method to reliably characterise the patient level of protection. Only poor correlations between protection and allergen-specific serum immunoglobulins have been found, and a sting challenge is the only means to evaluate the efficacy of immunotherapy. Therefore, we aimed to develop a cutaneous test that measures in vivo neutralisation of the Hymenoptera venom. Materials and Methods: Twenty-four patients with wasp venom allergy were included in the study. Wasp-specific serum IgE, IgG and IgG4 were measured by ImmunoCAP. Dilutions of the individual patient sera were intradermally injected into the forearm. Then, wasp venom extract was injected into these sites to quantitatively assess the formation of wheals and flares. Results: The results show that during the course of SIT, patient sera gained the capacity to neutralise skin reactions to wasp venom extracts in vivo. The test correlated with the duration of SIT as well as with the concentration of IgG and IgG4. Conclusion: The in vivo neutralisation test may become a promising tool in allergy diagnostics as well as in monitoring the success of SIT in patients undergoing allergen SIT.

1.
Incorvaia C, Senna G, Mauro M, Bonadonna P, Marconi I, Asero R, Nitti F: Prevalence of allergic reactions to Hymenoptera stings in northern Italy. Allerg Immunol (Paris) 2004;36:372–374.
2.
Biló BM, Rueff F, Mosbech H, Bonifazi F, Oude-Elberink JNG: Diagnosis of Hymenoptera venom allergy. Allergy 2005;60:1339–1349.
3.
Bonifazi F, Jutel M, Biló BM, Birnbaum J, Muller U: Prevention and treatment of hymenoptera venom allergy: guidelines for clinical practice. Allergy 2005;60:1459–1470.
4.
Day JH, Buckeridge DL, Welsh AC: Risk assessment in determining systemic reactivity to honeybee stings in sting-threatened individuals. J Allergy Clin Immunol 1994;93:691–705.
5.
Hepner MJ, Ownby DR, Anderson JA, Rowe MS, Sears-Ewald D, Brown EB: Risk of systemic reactions in patients taking beta-blocker drugs receiving allergen immunotherapy injections. J Allergy Clin Immunol 1990;86:407–411.
6.
Bousquet J, Lockey R, Malling HJ, Alvarez-Cuesta E, Canonica GW, Chapman MD, Creticos PJ, Dayer JM, Durham SR, Demoly P, Goldstein RJ, Ishikawa T, Ito K, Kraft D, Lambert PH, Lowenstein H, Muller U, Norman PS, Reisman RE, Valenta R, Valovirta E, Yssel H: Allergen immunotherapy: therapeutic vaccines for allergic diseases. World Health Organization. American Academy of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 1998;81:401–405.
7.
Norman PS: Immunotherapy: 1999–2004. J Allergy Clin Immunol 2004;113:1013–1023.
8.
Golden DB: Discontinuing venom immunotherapy. Curr Opin Allergy Clin Immunol 2001;1:353–356.
9.
Cantani A, Micera M: Significant decrease of IgE antibodies after a three-year controlled study of specific immunotherapy to pollen allergens in children with allergic asthma. Eur Rev Med Pharmacol Sci 2005;9:103–111.
10.
Wachholz PA, Durham SR: Mechanisms of immunotherapy: IgG revisited. Curr Opin Allergy Clin Immunol 2004;4:313–318.
11.
Akdis CA, Blesken T, Akdis M, Alkan SS, Wuthrich B, Heusser CH, Blaser K: Induction and differential regulation of bee venom phospholipase A2-specific human IgE and IgG4 antibodies in vitro requires allergen-specific and nonspecific activation of T and B cells. J Allergy Clin Immunol 1997;99:345–353.
12.
Robinson DS, Larche M, Durham SR: Tregs and allergic disease. J Clin Invest 2004;114:1389–1397.
13.
Wuthrich B: Classification of sting insect sensitivity. J Investig Allergol Clin Immunol 2001;11:132.
14.
Bousquet J, Lockey RF, Malling HJ: WHO position paper. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy 1998;53:1–42.
15.
Meier P, Muller U: Evaluation of IgG RAST FEIA for the assay of venom-specific IgG antibodies during venom immunotherapy. Int Arch Allergy Immunol 1998;117:46–51.
16.
Brockow K, Romano A, Blanca M, Ring J, Pichler W, Demoly P: General considerations for skin test procedures in the diagnosis of drug hypersensitivity. Allergy 2002;57:45–51.
17.
Sussman GL, Harvey RP, Schocket AL: Evaluation of skin test response using two techniques of measurement. Ann Allergy 1982;48:75–77.
18.
Freeman J: Further observations on the treatment of hay fever by hypodermic inoculations of pollen vaccine. Lancet 1911;178: 814–817.
19.
Noon L: Prophylactic inoculation against hay fever. Lancet 1911;177:1572–1573.
20.
Eng PA, Borer-Reinhold M, Heijnen IA, Gnehm HP: Twelve-year follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood. Allergy 2006;61:198–201.
21.
Pichler CE, Helbling A, Pichler WJ: Three years of specific immunotherapy with house-dust-mite extracts in patients with rhinitis and asthma: significant improvement of allergen-specific parameters and of nonspecific bronchial hyperreactivity. Allergy 2001;56:301–306.
22.
Golden DB, Kagey-Sobotka A, Valentine MD, Lichtenstein LM: Dose dependence of Hymenoptera venom immunotherapy. J Allergy Clin Immunol 1981;67:370–374.
23.
Golden DB, Kagey-Sobotka A, Norman PS, Hamilton RG, Lichtenstein LM: Outcomes of allergy to insect stings in children, with and without venom immunotherapy. N Engl J Med 2004;351:668–674.
24.
Hunt KJ, Valentine MD, Sobotka AK, Benton AW, Amodio FJ, Lichtenstein LM: A controlled trial of immunotherapy in insect hypersensitivity. N Engl J Med 1978;299:157–161.
25.
Muller U, Helbling A, Berchtold E: Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety. J Allergy Clin Immunol 1992;89:529–535.
26.
Wyss M, Scheitlin T, Stadler BM, Wuthrich B: Immunotherapy with aluminum hydroxide adsorbed insect venom extracts (Alutard SQ): immunologic and clinical results of a prospective study over 3 years. Allergy 1993;48:81–86.
27.
Pereira C, Botelho F, Tavares B, Lourenco C, Baeta C, Palma-Carlos AG, Lima J, Chieira C: Kinetics and dynamic evaluation of specific immunotherapy. Allerg Immunol (Paris) 2004;36:375–386.
28.
Yunginger JW, Jones RT, Leiferman KM, Paull BR, Welsh PW, Gleich GJ: Immunological and biochemical studies in beekeepers and their family members. J Allergy Clin Immunol 1978;61:93–101.
29.
Golden DB, Lawrence ID, Hamilton RH, Kagey-Sobotka A, Valentine MD, Lichtenstein LM: Clinical correlation of the venom-specific IgG antibody level during maintenance venom immunotherapy. J Allergy Clin Immunol 1992;90:386–393.
30.
Bousquet J, Coulomb Y, Robinet-Levy M, Michel FB: Clinical and immunological surveys in bee keepers. Clin Allergy 1982;12:331–342.
31.
Wetterwald A, Skvaril F, Muller U, Blaser K: Isotypic and idiotypic characterization of anti-bee venom phospholipase A2 antibodies. Int Arch Allergy Appl Immunol 1985;77:195–197.
32.
Aalberse RC, van der Gaag R, van Leeuwen J: Serologic aspects of IgG4 antibodies. 1. Prolonged immunization results in an IgG4-restricted response. J Immunol 1983;130:722–726.
33.
Muller UR, Morris T, Bischof M, Friedli H, Skarvil F: Combined active and passive immunotherapy in honeybee-sting allergy. J Allergy Clin Immunol 1986;78:115–122.
34.
Bousquet J, Fontez A, Aznar R, Robinet-Levy M, Michel FB: Combination of passive and active immunization in honeybee venom immunotherapy. J Allergy Clin Immunol 1987;79:947–954.
35.
Wilson AB, Deighton J, Lachmann PJ, Ewan PW: A comparative study of IgG subclass antibodies in patients allergic to wasp or bee venom. Allergy 1994;49:272–280.
36.
Bousquet J, Chanez P, Chanal I, Michel FB: Comparison between RAST and Pharmacia CAP system: a new automated specific IgE assay. J Allergy Clin Immunol 1990;85:1039–1043.
37.
Ewan PW, Coote D: Evaluation of a capsulated hydrophilic carrier polymer (the ImmunoCAP) for measurement of specific IgE antibodies. Allergy 1990;45:22–29.
38.
Jeep S, Kirchhof E, O’Connor A, Kunkel G: Comparison of the Phadebas RAST with the Pharmacia CAP system for insect venom. Allergy 1992;47:212–217.
39.
Leimgruber A, Lantin JP, Frei PC: Comparison of two in vitro assays, RAST and CAP, when applied to the diagnosis of anaphylactic reactions to honeybee or yellow jacket venoms. Correlation with history and skin tests. Allergy 1993;48:415–420.
40.
Bachmann MF, Kalinke U, Althage A, Freer G, Burkhart C, Roost H, Aguet M, Hengartner H, Zinkernagel RM: The role of antibody concentration and avidity in antiviral protection. Science 1997;276:2024–2027.
41.
Foote J, Milstein C: Kinetic maturation of an immune response. Nature 1991;352:530–532.
42.
Milstein C: Affinity maturation of antibodies. Immunol Today 1991;12:93–94.
43.
Ewan PW, Deighton J, Wilson AB, Lachmann PJ: Venom-specific IgG antibodies in bee and wasp allergy: lack of correlation with protection from stings. Clin Exp Allergy 1993;23:647–660.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.